COMP <GO>
IMCR vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Immunocore Holdings plc (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: IMCR 2
— MRK 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $30.49 (-2.49%) • MKT CAP: $1.61B
roic
-35.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMCR VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMCR | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | IMCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.93% | 3.42% | -4.35 | MRK | /fcf-yield <GO> |
| Operating Margin | -11.30% | 34.30% | -45.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -8.90% | 28.10% | -37.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 29.00% | 1.30% | +27.70 | IMCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.40 | 5.19 | -3.79 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.8 | 51.7 | -0.90 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $361.02B | -$359.41B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMCR REV | MRK REV | IMCR GROSS % | MRK GROSS % | IMCR FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $400.0M | $65.01B | 98.0% | 74.8% | -$15.1M | $12.36B |
| FY 2024 | $310.2M | $64.17B | 98.0% | 76.3% | $20.9M | $18.10B |
| FY 2023 | $249.4M | $60.12B | — | — | $2.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMCR // BETA —
MRK // BETA 0.92